Hengrui Medicine: The application for the market approval of injection of methyl sulphate rilmazolam has been accepted by the National Medical Products Administration.

Hengrui Medicine announced that recently, the company's injection of remimazolam besylate drug has obtained approval for market authorization application from the National Medical Products Administration. This drug is a short-acting GABAa receptor agonist, with advantages such as fast onset, short recovery time, and minimal impact on the respiratory and cardiovascular systems. Previously, injection of remimazolam besylate had been approved for sedation and anesthesia in non-tracheal intubation surgery/procedures, as well as for induction and maintenance of general anesthesia.